Last reviewed · How we verify
A Single Part, Four-Way Crossover, Randomized, Partially-Blinded Study to Evaluate the Effect of Intravenous ANG-3777 on Baseline-Adjusted QT/QTc Interval in the Fasted State in Healthy Male and Female Subjects
The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.
Details
| Lead sponsor | Angion Biomedica Corp |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 48 |
| Start date | 2021-06 |
| Completion | 2021-09 |
Conditions
- Healthy Volunteer
Interventions
- ANG-3777 (Therapeutic Dose)
- ANG-3777 (Supra-therapeutic Dose)
- Placebo
- Moxifloxacin Hydrochloride
Primary outcomes
- Change from baseline in corrected QT interval by Fridericia's formula for ANG-3777 at the therapeutic and supra-therapeutic dose levels compared to placebo — Day 1, Day 5, Day 9 and Day 13
Countries
United States